Search for content, post, videos

First patient dosed in Targovax study

Targovax has announced that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in the USA. The study is led by gastrointestinal cancer expert Dr. Anup Kasi in a three-way clinical coll
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.